Antiretroviral therapy for prevention of HIV transmission: Implications for Europe

Eurosurveillance

Volumn 18, Issue 48, 2013, Pages

  Cambiano, V ^a   O'Connor, J ^a   Phillips, A N ^a   Rodger, A ^a   Lodwick, R ^a   Pharris, A ^b   Lampe, F ^a   Nakagawa, F ^a   Smith, C ^a   van de Laar, M J ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b EUROPEAN CENTRE FOR DISEASE PREVENTION AND CONTROL ECDC   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT;

CD4 LYMPHOCYTE COUNT; CONDOM USE; DRUG USE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MEN WHO HAVE SEX WITH MEN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL TRANSMISSION; SYSTEMATIC REVIEW; VIRUS LOAD; VIRUS TRANSMISSION; ADULT; EUROPE; FEMALE; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; SEXUALITY; TRANSMISSION;

ADULT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; ELIGIBILITY DETERMINATION; EUROPE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; SEXUAL PARTNERS;

EID: 84888596813     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2013.18.48.20647     Document Type: Review

References (119)

1. European Centre for Disease Prevention and Control (ECDC)/WHO Regional Office for Europe. HIV/AIDS surveillance in Europe 2012. Stockholm: ECDC; 2013. Available from: http://ecdc.europa.eu/en/publications/Publications/hiv-aids-surveillance-report-2012-20131127.pdf
2. Egger M, May M, Chêne G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360(9327):119-29. http://dx.doi.org/10.1016/S0140-6736(02)09411-4
3. May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368(9534):451-8.http://dx.doi.org/10.1016/S0140-6736(06)69152-6
4. Staszewski S, Miller V, Sabin C, Carlebach A, Berger AM, Weidmann E, et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS. 1999;13(3):367-73. http://dx.doi.org/10.1097/00002030-199902250-00009 PMid:10199227
5. Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, et al. Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5(9):e12598. http://dx.doi.org/10.1371/journal.pone.0012598 PMid:20856886 PMCid:PMC2938354
6. Del Romero J, Castilla J, Hernando V, Rodríguez C, García S. Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ. 2010;340:c2205. http://dx.doi.org/10.1136/bmj.c2205 PMid:20472675 PMCid:PMC2871073
7. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342(13):921-9. http://dx.doi.org/10.1056/NEJM200003303421303 PMid:10738050
8. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis. 2005;191(9):1403-9. http://dx.doi.org/10.1086/429411 PMid:15809897
9. Vernazza P, Hirschel B, Bernasconi E, Flepp M. Les personnes seropositives ne souffrant d'aucune autre MST et suivant untraitment antiretroviral efficace ne transmettent pas le VIH par voie sexuelle. [HIV-positive individuals not suffering from any other STD and adhering to an effective antiretroviral treatment do not transmit HIV sexually]. Bulletin des Médecins Suisses. 2008;89:165-9. French. Available from: http://www.gayromandie.ch/IMG/pdf/Les_personnes_seropositives_ne_souffrant_d_aucune_autre_MST_et_suivant_un_traitement_antiretroviral_efficace_ne_transmettent_pas_le_VIH_par_voie_sexuelle.pdf
10. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011; 365(6):493-505. http://dx.doi.org/10.1056/NEJMoa1105243 PMid:21767103 PMCid:PMC3200068
11. Thompson MA, Aberg JA, Hoy JF, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012;308(4):387-402. http://dx.doi.org/10.1001/jama.2012.7961 PMid:22820792
12. Panel on Antiretroviral Guidelines for Adults and Adolescents, Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf
13. European Centre for Disease Prevention and Control (ECDC) Evaluating HIV treatment as prevention in the European context. Stockholm: ECDC; 2012. Available from: http://ecdc.europa.eu/en/publications/publications/hiv-treatment-as-prevention.pdf
14. Mehendale SM, Ghate MV, Kishore Kumar B, Sahay S, Gamble TR, Godbole SV, et al. Low HIV-1 incidence among married serodiscordant couples in Pune, India. J Acquir Immune Defic Syndr. 2006;41(3):371-3. http://dx.doi.org/10.1097/01.qai.0000209905.35620.48PMid:16540940
15. Fideli US, Allen SA, Musonda R, Trask S, Hahn BH, Weiss H, et al. Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses. 2001;17(10):901-10. http://dx.doi.org/10.1089/088922201750290023 PMid:11461676 PMCid:PMC2748905
16. Tovanabutra S, Robison V, Wongtrakul J, Sennum S, Suriyanon V, Kingkeow D, et al. Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr. 2002;29(3):275-83. http://dx.doi.org/10.1097/00042560-200203010-00008 PMid:11873077
17. Melo MG, Santos BR, De Cassia LR, Varella IS, Turella ML, Rocha TM, et al. Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis. 2008;35(11):912-5. http://dx.doi.org/10.1097/OLQ.0b013e31817e2491 PMid:18607309
18. Castilla J, Del Romero J, Hernando V, Marincovich B, García S, Rodríguez C. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr. 2005;40(1):96-101. http://dx.doi.org/10.1097/01.qai.0000157389.78374.45 PMid:16123689
19. Donnell D, Baeten JM, Kiarie J, Thomas KK, Stevens W, Cohen CR, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010;375(9731):2092-8. http://dx.doi.org/10.1016/S0140-6736(10)60705-2
20. Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397-404. http://dx.doi.org/10.1097/QAD.0b013e32832b7dca PMid:19381076
21. Anglemyer A, Horvath T, Rutherford G. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. JAMA. 2013;310(15):1619-20. http://dx.doi.org/10.1001/jama.2013.278328 PMid:24129466
22. Anglemyer A, Rutherford G, Baggaley R, Egger M, Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples: a systematic review of the observational literature. J Int AIDS Soc. 2012;15:145-6. Conference abstract available from: http://www.jiasociety.org/index.php/jias/article/view/18440/1244
23. Baggaley RF, White RG, Hollingsworth TD, Boily MC. Heterosexual HIV-1 infectiousness and antiretroviral use: systematic review of prospective studies of discordant couples. Epidemiology. 2013;24(1):110-21. http://dx.doi.org/10.1097/EDE.0b013e318276cad7 PMid:23222513
24. Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS One. 2013;8(2):e55747. http://dx.doi.org/10.1371/journal.pone.0055747 PMid:23418455 PMCid:PMC3572113
25. Reynolds SJ, Makumbi F, Nakigozi G, Kagaayi J, Gray RH, Wawer M, et al. HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011;25(4):473-7. http://dx.doi.org/10.1097/QAD.0b013e3283437c2b PMid:21160416 PMCid:PMC3261071
26. Sullivan P, Kayitenkore K, Chomba E, Karita E, Mwananyanda L, Vwalika C, et al. Is the reduction of HIV transmission risk while prescribed antiretroviral therapy (ARVT) different for men and women? Results from discordant couples in Rwanda and Zambia. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 19-22 July 2009, Cape Town, South Africa. Available from: http://www.ias2009.org/pag/PosterExhibition.aspx
27. Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet. 2013;382(9899):1195-203. http://dx.doi.org/10.1016/S0140-6736(12)61898-4
28. Wang L, Ge Z, Luo J, Shan D, Gao X, Ding GW, et al. HIV Transmission Risk Among Serodiscordant Couples: A Retrospective Study of Former Plasma Donors in Henan, China. J Acquir Immune Defic Syndr. 2010;55(2):232-8. http://dx.doi.org/10.1097/QAI.0b013e3181e9b6b7 PMid:21423851 PMCid:PMC3058178
29. Birungi J, Wang H, Ngolobe M, Muldoon K, Khanakwa S, King R et al. Lack of effectiveness of antiretroviral therapy (ART) as an HIV prevention tool for serodiscordant couples in a rural ART program without viral load monitoring in Uganda. J Int AIDS Society. 2012;15:144-5. Conference abstract available from: http://www.jiasociety.org/index.php/jias/article/view/18440/1244
30. Tanser F, Bärnighausen T, Grapsa E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339(6122):966-71. http://dx.doi.org/10.1126/science.1228160 PMid:23430656
31. Muessig KE, Smith MK, Powers KA, Lo YR, Burns DN, Grulich AE, et al. Does ART prevent HIV transmission among MSM? AIDS. 2012;26(18):2267-73. http://dx.doi.org/10.1097/QAD.0b013e328355713dn PMid:22569019 PMCid:PMC3499670
32. Wilson DP, Jin F, Jansson J, Zablotska I, Grulich AE. Infectiousness of HIV-infected men who have sex with men in the era of highly active antiretroviral therapy. AIDS. 2010;24(15):2420-1. http://dx.doi.org/10.1097/QAD.0b013e32833dbdb1 PMid:20827060
33. Baggaley RF, White RG, Boily MC. HIV transmission risk through anal intercourse: systematic review, meta-analysis and implications for HIV prevention. Int J Epidemiol. 2010;39(4):1048-1063. http://dx.doi.org/10.1093/ije/dyq057 PMid:20406794 PMCid:PMC2929353
34. Salomon JA, Hogan DR. Evaluating the impact of antiretroviral therapy on HIV transmission. AIDS. 2008;22 Suppl 1:S149-59. http://dx.doi.org/10.1097/01.aids.0000327636.82542.87 PMid:18664947
35. Modjarrad K, Chamot E, Vermund SH. Impact of small reductions in plasma HIV RNA levels on the risk of heterosexual transmission and disease progression. AIDS. 2008;22(16):2179-85. http://dx.doi.org/10.1097/QAD.0b013e328312c756 PMid:18832881 PMCid:PMC2661869
36. Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet. 2008;372(9652):314-20. http://dx.doi.org/10.1016/S0140-6736(08)61115-0
37. Jin F, Jansson J, Law M, Prestage GP, Zablotska I, Imrie JC, et al. Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS. 2010;24(6):907-13. http://dx.doi.org/10.1097/QAD.0b013e3283372d90 PMid:20139750 PMCid:PMC2852627
38. Baggaley RF, White RG, Boily MC. Infectiousness of HIV-infected homosexual men in the era of highly active antiretroviral therapy. AIDS. 2010;24(15):2418-20. http://dx.doi.org/10.1097/QAD.0b013e32833dbdfd PMid:20827059 PMCid:PMC2958037
39. Wilson DP. Data are lacking for quantifying HIV transmission risk in the presence of effective antiretroviral therapy. AIDS. 2009;23(11):1431-3. http://dx.doi.org/10.1097/QAD.0b013e32832d871b PMid:19487904
40. Vittinghoff E, Douglas J, Judson F, McKirnan D, MacQueen K, Buchbinder SP. Per-contact risk of human immunodeficiency virus transmission between male sexual partners. Am J Epidemiol. 1999;150(3):306-11. http://dx.doi.org/10.1093/oxfordjournals.aje.a010003 PMid:10430236
41. DeGruttola V, Seage GR 3rd, Mayer KH, Horsburgh CR Jr. Infectiousness of HIV between male homosexual partners. J Clin Epidemiol. 1989;42(9):849-56. http://dx.doi.org/10.1016/0895-4356(89)90098-X
42. de Vincenzi I. A longitudinal study of human immunodeficiency virus transmission by heterosexual partners. European Study Group on Heterosexual Transmission of HIV. N Engl J Med. 1994;331(6):341-6. http://dx.doi.org/10.1056/NEJM199408113310601 PMid:8028613
43. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118-29. http://dx.doi.org/10.1016/S1473-3099(09)70021-0
44. Health Protection Agency (HPA). Sexually transmitted infections in men who have sex with men in the UK: 2011 report. London: HPA; 2011. http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317131685989
45. Truong HM, Kellogg T, Klausner JD, Katz MH, Dilley J, Knapper K, et al. Increases in sexually transmitted infections and sexual risk behaviour without a concurrent increase in HIV incidence among men who have sex with men in San Francisco: a suggestion of HIV serosorting? Sex Transm Infect. 2006;82(6):461-6. http://dx.doi.org/10.1136/sti.2006.019950 PMid:17151031 PMCid:PMC2563862
46. Williamson LM, Dodds JP, Mercey DE, Hart GJ, Johnson AM. Sexual risk behaviour and knowledge of HIV status among community samples of gay men in the UK. AIDS. 2008;22(9):1063-70. http://dx.doi.org/10.1097/QAD.0b013e3282f8af9b PMid:18520350
47. Hasse B, Ledergerber B, Hirschel B, Vernazza P, Glass TR, Jeannin A, et al. Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis. 2010;51(11):1314-22. http://dx.doi.org/10.1086/656809 PMid:21034200
48. Rodger A, Bruun T, Weait M, Vernazza P, Collins S, Estrada V, et al. Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods. BMC Public Health. 2012;12:296. http://dx.doi.org/10.1186/1471-2458-12-296 PMid:22520171 PMCid:PMC3382424
49. Lampe F, Speakman A, Phillips AN, Sherr L, Gilson R, Johnson MA, et al. ART use, viral suppression, and sexual behaviour among HIV-diagnosed MSM in the UK: results from the ASTRA (Antiretrovirals, Sexual Transmission Risk and Attitudes) Study. Eleventh International Congress on Drug Therapy in HIV Infection, 11-15 November 2012, Glasgow, United Kingdom. Available from: http://www.jiasociety.org/index.php/jias/article/view/18143
50. Crepaz N, Hart TA, Marks G. Highly active antiretroviral therapy and sexual risk behavior: a meta-analytic review. JAMA. 2004;292(2):224-36. http://dx.doi.org/10.1001/jama.292.2.224 PMid:15249572
51. World Health Organization (WHO). Guidance on couples HIV testing and counselling, including antiretroviral therapy for treatment and prevention in serodiscordant couples. Recommendations for a public health approach. Geneva: WHO; 2012. Available from: http://www.who.int/hiv/pub/guidelines/9789241501972/en/index.html
52. Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med. 2012;13 Suppl 2:1-85. http://dx.doi.org/10.1111/j.1468-1293.2012.01029.x
53. World Health Organization (WHO). Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: WHO; 2013. Available from: http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf
54. European AIDS Clinical Society (EACS). EACS Guidelines, Version 7.0. October 2013. [Accessed 26 Nov 2013]. Available from: http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf
55. Sabin CA, Cooper DA, Collins S, Schechter M. Rating evidence in treatment guidelines: a case example of when to initiate combination antiretroviral therapy (cART) in HIV-positive asymptomatic persons. AIDS. 2013;27(12):1839-46. http://dx.doi.org/10.1097/QAD.0b013e328360d546 PMid:24179998
56. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133-44. http://dx.doi.org/10.1086/586713 PMid:18476292
57. Strategic Timing of Antiretroviral Treatment (START). ClinicalTrials.gov [Accessed 20 Nov 2011]. Available from: http://clinicaltrials.gov/ct2/show/NCT00867048
58. Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO). ClinicalTrials.gov. [Accessed 26 Nov 2013]. Available from: http://clinicaltrials.gov/show/NCT00495651
59. Cohen MS, Smith MK, Muessig KE, Hallett TB, Powers KA, Kashuba AD. Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet. 2013;382(9903):1515-24. http://dx.doi.org/10.1016/S0140-6736(13)61998-4
60. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, et al. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ cell counts and HIV RNA levels during follow-up. J Infect Dis. 2008;197(8):1145-55. http://dx.doi.org/10.1086/529523 PMid:18476293
61. Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, et al. Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 cells/mm3: assessment of need following changes in treatment guidelines. Clin Infect Dis. 2011;53(8):817-25. http://dx.doi.org/10.1093/cid/cir494 PMid:21921225
62. Mocroft A, Lundgren JD, Sabin ML, Monforte Ad, Brockmeyer N, Casabona J, et al. Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013;10(9):e1001510. http://dx.doi.org/10.1371/journal.pmed.1001510 PMid:24137103 PMCid:PMC3796947
63. PopART. London: Imperial College London. [Accessed 16 Apr 2012]. Available from: http://www1.imperial.ac.uk/medicine/research/researchthemes/infection/infectious_diseases/hiv_trials/hiv_prevention_technologies/popart/about/
64. Treatment As Prevention (Tasp) trial. KwaZulu-Natal: Africa Centre. [Accessed 16 Apr 2012]. Available from: http://www.africacentre.ac.za/NewsArchives/2010Archives/FrenchAIDSResearchAgencyawardsAfricaCentre/tabid/439/Default.aspx
65. An HIV Prevention Program for Mochudi, Botswana. Lambertville, NJ: Labome.Org. [Accessed 16 Apr 2012]. Available from: http://www.labome.org/grant/r01/ai/an/hiv/an-hiv-prevention-program-for-mochudi--botswana-7680502.html
66. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010; 5(6):e11068. http://dx.doi.org/10.1371/journal.pone.0011068 PMid:20548786 PMCid:PMC2883572
67. Dukers NH, Spaargaren J, Geskus RB, Beijnen J, Coutinho RA, Fennema HS. HIV incidence on the increase among homosexual men attending an Amsterdam sexually transmitted disease clinic: using a novel approach for detecting recent infections. AIDS. 2002;16(10):F19-24. http://dx.doi.org/10.1097/00002030-200207050-00001 PMid:12131206
68. Fang CT, Hsu HM, Twu SJ, Chen MY, Chang YY, Hwang JS, et al. Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis. 2004;190(5):879-85. http://dx.doi.org/10.1086/422601 PMid:15295691
69. Fisher M, Pao D, Murphy G, Dean G, McElborough D, Homer G, et al. Serological testing algorithm shows rising HIV incidence in a UK cohort of men who have sex with men: 10 years application. AIDS. 2007;21(17):2309-14. http://dx.doi.org/10.1097/QAD.0b013e3282ef9fed PMid:18090279
70. Grulich AE, Kaldor JM. Trends in HIV incidence in homosexual men in developed countries. Sex Health. 2008;5(2):113-8. http://dx.doi.org/10.1071/SH07075
71. Montaner JS, Lima VD, Barrios R, Yip B, Wood E, Kerr T, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet. 2010;376(9740):532-9. http://dx.doi.org/10.1016/S0140-6736(10)60936-1
72. Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447-58. http://dx.doi.org/10.1097/QAD.0b013e32835ca2dd PMid:23296196
73. Andrews JR, Wood R, Bekker LG, Middelkoop K, Walensky RP. Projecting the benefits of antiretroviral therapy for HIV prevention: the impact of population mobility and linkage to care. J Infect Dis. 2012;206(4):543-51. http://dx.doi.org/10.1093/infdis/jis401 PMid:22711905 PMCid:PMC3491737
74. Abbas UL, Anderson RM, Mellors JW. Potential impact of antiretroviral therapy on HIV-1 transmission and AIDS mortality in resource-limited settings. J Acquir Immune Defic Syndr. 2006;41(5):632-41. http://dx.doi.org/10.1097/01.qai.0000194234.31078.bf PMid:16652038
75. Baggaley RF, Garnett GP, Ferguson NM. Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med. 2006;3(4):e124. http://dx.doi.org/10.1371/journal.pmed.0030124 PMid:16519553 PMCid:PMC1395349
76. Bendavid E, Brandeau ML, Wood R, Owens DK. Comparative effectiveness of HIV testing and treatment in highly endemic regions. Arch Intern Med. 2010;170(15):1347-54. http://dx.doi.org/10.1001/archinternmed.2010.249 PMid:20696960 PMCid:PMC2921232
77. El-Sadr WM, Coburn BJ, Blower S. Modeling the impact on the HIV epidemic of treating discordant couples with antiretrovirals to prevent transmission. AIDS. 2011;25(18):2295-9. http://dx.doi.org/10.1097/QAD.0b013e32834c4c22 PMid:21993304
78. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48-57. http://dx.doi.org/10.1016/S0140-6736(08)61697-9
79. Johnson LF, Hallett TB, Rehle TM, Dorrington RE. The effect of changes in condom usage and antiretroviral treatment coverage on human immunodeficiency virus incidence in South Africa: a model-based analysis. J R Soc Interface. 2012;9(72):1544-54. http://dx.doi.org/10.1098/rsif.2011.0826 PMid:22258551 PMCid:PMC3367823
80. Murnane PM, Hughes JP, Celum C, Lingappa JR, Mugo N, Farquhar C, et al. Using plasma viral;load to guide antiretroviral therapy initiation to prevent HIV-1 transmission. PLoS One. 2012;7(11):e51192. http://dx.doi.org/10.1371/journal.pone.0051192 PMid:23250272 PMCid:PMC3511400
81. Palombi L, Bernava GM, Nucita A, Giglio P, Liotta G, Nielsen-Saines K, et al. Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the Drug Resource Enhancement Against AIDS and Malnutrition Model: antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district level. Clin Infect Dis. 2012;55(2):268-75. http://dx.doi.org/10.1093/cid/cis380 PMid:22491503
82. Wagner BG, Coburn BJ, Blower S. Increasing survival time decreases the cost-effectiveness of using test & treat to eliminate HIV epidemics. Math Biosci Eng. 2013;10(5-6):1673-86. PMid:24245641
83. Walensky RP, Ross EL, Kumarasamy N, Wood R, Noubary F, Paltiel AD, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013;369(18):1715-25. http://dx.doi.org/10.1056/NEJMsa1214720 PMid:24171517
84. Yusuf TT, Benyah F. Optimal strategy for controlling the spread of HIV/AIDS disease: a case study of South Africa. J Biol Dyn. 2012;6(2):475-94. http://dx.doi.org/10.1080/17513758.2011.628700 PMid:22873601
85. Alsallaq RA, Baeten JM, Celum CL, Hughes JP, Abu-Raddad LJ, Barnabas RV, et al. Understanding the potential impact of a combination HIV prevention intervention in a hyper-endemic community. PLoS One. 2013;8(1):e54575. http://dx.doi.org/10.1371/journal.pone.0054575 PMid:23372738 PMCid:PMC3553021
86. Anglaret X, Scott CA, Walensky RP, Ouattara E, Losina E, Moh R, et al. Could early antiretroviral therapy entail more risks than benefits in sub-Saharan African HIV-infected adults? A model-based analysis. Antivir Ther. 2013;18(1):45-55. http://dx.doi.org/10.3851/IMP2231 PMid:22809695
87. Bärnighausen T, Bloom DE, Humair S. Economics of antiretroviral treatment vs. circumcision for HIV prevention. Proc Natl Acad Sci U S A. 2012;109(52):21271-6. http://dx.doi.org/10.1073/pnas.1209017110 PMid:23223563 PMCid:PMC3535659
88. Eaton JW, Johnson LF, Salomon JA, Bärnighausen T, Bendavid E, Bershteyn A, et al. HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa. PloS Med. 2012;9(7):e1001245. http://dx.doi.org/10.1371/journal.pmed.1001245 PMid:22802730 PMCid:PMC3393664
89. Granich R, Kahn JG, Bennett R, Holmes CB, Garg N, Serenata C, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011-2050. PLoS One. 2012; 7(2):e30216. http://dx.doi.org/10.1371/journal.pone.0030216 PMid:22348000 PMCid:PMC3278413
90. Long EF, Brandeau ML, Owens DK. The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med. 2010;153(12):778-89. http://dx.doi.org/10.7326/0003-4819-153-12-201012210-00004 PMid:21173412 PMCid:PMC3173812
91. Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4):392-400. http://dx.doi.org/10.1086/655130 PMid:20617921 PMCid:PMC2906630
92. Li J, Gilmour S, Zhang H, Koyanagi A, Shibuya K. The epidemiological impact and cost-effectiveness of HIV testing, antiretroviral treatment and harm reduction programs. AIDS. 2012;26(16):2069-78. http://dx.doi.org/10.1097/QAD.0b013e3283574e54 PMid:22781221
93. Lou J, Wu J, Chen L, Ruan Y, Shao Y. A sex-role-preference model for HIV transmission among men who have sex with men in China. BMC Public Health. 2009;9 Suppl 1:S10. http://dx.doi.org/10.1186/1471-2458-9-S1-S10 PMid:19922680 PMCid:PMC2779498
94. Zhang L, Gray RT, Wilson DP. Modelling the epidemiological impact of scaling up HIV testing and antiretroviral treatment in China. Sex Health. 2012;9(3):261-71. http://dx.doi.org/10.1071/SH11104 PMid:22697144
95. Ramadanovic B, Vasarhelyi K, Nadaf A, Wittenberg RW, Montaner JS, Wood E, et al. Changing risk behaviours and the HIV epidemic: a mathematical analysis in the context of treatment as prevention. PLoS One. 2013;8(5):e62321. http://dx.doi.org/10.1371/journal.pone.0062321 PMid:23671592 PMCid:PMC3646049
96. Heymer KJ, Wilson DP. Treatment for prevention of HIV transmission in a localised epidemic: the case for South Australia. Sex Health. 2011;8(3):280-94. http://dx.doi.org/10.1071/SH10084 PMid:21851767
97. Law MG, Prestage G, Grulich A, Van de Ven P, Kippax S. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS. 2001;15(10):1287-94. http://dx.doi.org/10.1097/00002030-200107060-00011 PMid:11426074
98. Wirtz AL, Walker DG, Bollinger L, Sifakis F, Baral S, Johns B, et al. Modelling the impact of HIV prevention and treatment for men who have sex with men on HIV epidemic trajectories in low- and middle-income countries. Int J STD AIDS. 2013;24(1):18-30. http://dx.doi.org/10.1177/0956462412472291 PMid:23512511
99. Sorensen SW, Sansom SL, Brooks JT, Marks G, Begier EM, Buchacz K, et al. A mathematical model of comprehensive test-and-treat services and HIV incidence among men who have sex with men in the United States. PLoS One. 2012;7(2):e29098. http://dx.doi.org/10.1371/journal.pone.0029098 PMid:22347994 PMCid:PMC3277596
100. Charlebois ED, Das M, Porco TC, Havlir DV. The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco. Clin Infect Dis. 2011;52(8):1046-9. http://dx.doi.org/10.1093/cid/cir085 PMid:21460322 PMCid:PMC3070031
101. Sood N, Wagner Z, Jaycocks A, Drabo E, Vardavas R. Test-and-treat in Los Angeles: a mathematical model of the effects of test-and-treat for the population of men who have sex with men in Los Angeles County. Clin Infect Dis. 2013;56(12):1789-1796. http://dx.doi.org/10.1093/cid/cit158 PMid:23487387
102. Blower SM, Gershengorn HB, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science. 2000;287(5453):650-4. http://dx.doi.org/10.1126/science.287.5453.650 PMid:10649998
103. McCormick AW, Walensky RP, Lipsitch M, Losina E, Hsu H, Weinstein MC, et al. The effect of antiretroviral therapy on secondary transmission of HIV among men who have sex with men. Clin Infect Dis. 2007;44(8):1115-22. http://dx.doi.org/10.1086/512816 PMid:17366461 PMCid:PMC2365722
104. Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth T, Prins M, et al. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy. AIDS. 2008;22(9):1071-7. http://dx.doi.org/10.1097/QAD.0b013e3282fd167c PMid:18520351
105. Brown AE, Gill ON, Delpech VC. HIV treatment as prevention among men who have sex with men in the UK: is transmission controlled by universal access to HIV treatment and care? HIV Med. 2013;14(9):563-70. http://dx.doi.org/10.1111/hiv.12066 PMid:23890150
106. Phillips AN, Cambiano V, Nakagawa F, Brown AE, Lampe F, Rodge A, et al. Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One. 2013;8(2):e55312. http://dx.doi.org/10.1371/journal.pone.0055312 PMid:23457467 PMCid:PMC3574102
107. Kretzschmar ME, Schim van der Loeff MF, Birrell PJ, De Angelis D, Coutinho RA. Prospects of elimination of HIV with test-and-treat strategy. Proc Natl Acad Sci U S A. 2013;110(39):15538-43. http://dx.doi.org/10.1073/pnas.1301801110 PMid:24009342
108. Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Schwartz A, et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS. 2006;20(17):2207-15. http://dx.doi.org/10.1097/QAD.0b013e328010c7d0 PMid:17086061
109. Hollingsworth TD, Anderson RM, Fraser C. HIV-1 transmission, by stage of infection. J Infect Dis. 2008;198(5):687-93. http://dx.doi.org/10.1086/590501 PMid:18662132
110. Miller WC, Rosenberg NE, Rutstein SE, Powers KA. Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS. 2010;5(4):277-82. http://dx.doi.org/10.1097/COH.0b013e32833a0d3a PMid:20543601 PMCid:PMC3130067
111. Powers KA, Ghani AC, Miller WC, Hoffman IF, Pettifor AE, Kamanga G, et al. The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet. 2011;378(9787):256-68. http://dx.doi.org/10.1016/S0140-6736(11)60842-8
112. Koopman JS, Jacquez JA, Welch GW, Simon CP, Foxman B, Pollock SM, et al. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14(3):249-58. http://dx.doi.org/10.1097/00042560-199703010-00009 PMid:9117458
113. Gnanakaran S, Bhattacharya T, Daniels M, Keele BF, Hraber PT, Lapedes AS, et al. Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog. 2011;7(9):e1002209. http://dx.doi.org/10.1371/journal.ppat.1002209 PMid:21980282 PMCid:PMC3182927
114. Nawaz F, Cicala C, Van Ryk D, Block KE, Jelicic K, McNally JP, et al. The genotype of early-transmitting HIV gp120s promotes alpha (4) beta(7)-reactivity, revealing alpha (4) beta(7) +/CD4+ T cells as key targets in mucosal transmission. PLoS Pathog. 2011;7(2):e1001301. http://dx.doi.org/10.1371/journal.ppat.1001301 PMid:21383973 PMCid:PMC3044691
115. Lewis F, Hughes GJ, Rambaut A, Pozniak A, Leigh Brown AJ. Episodic sexual transmission of HIV revealed by molecular phylodynamics. PLoS Med. 2008;5(3):e50. http://dx.doi.org/10.1371/journal.pmed.0050050 PMid:18351795 PMCid:PMC2267814
116. Fisher M, Pao D, Brown AE, Sudarshi D, Gill ON, Cane P, et al. Determinants of HIV-1 transmission in men who have sex with men: a combined clinical, epidemiological and phylogenetic approach. AIDS. 2010;24(11):1739-47. http://dx.doi.org/10.1097/QAD.0b013e32833ac9e6 PMid:20588173
117. Pao D, Fisher M, Hué S, Dean G, Murphy G, Cane PA, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS. 2005;19(1):85-90. http://dx.doi.org/10.1097/00002030-200501030-00010 PMid:15627037
118. Brenner BG, Roger M, Routy JP, Moisi D, Ntemgwa M, Matte C, et al. High rates of forward transmission events after acute/early HIV-1 infection. J Infect Dis. 2007;195(7):951-9. http://dx.doi.org/10.1086/512088 PMid:17330784
119. Apondi R, Bunnell R, Ekwaru JP, Moore D, Bechange S, Khana K, et al. Sexual behavior and HIV transmission risk of Ugandan adults taking antiretroviral therapy: 3 year follow-up. AIDS. 2011;25(10):1317-27. http://dx.doi.org/10.1097/QAD.0b013e328347f775 PMid:21522005